<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675970</url>
  </required_header>
  <id_info>
    <org_study_id>UAB1220-2</org_study_id>
    <nct_id>NCT04675970</nct_id>
  </id_info>
  <brief_title>Long Term Follow up Patients With Premature Ovarian Failure ex Vivo Gene Therapy</brief_title>
  <acronym>UB-OVF</acronym>
  <official_title>Long Term Follow up Patients With Premature Ovarian Failure ex Vivo Gene Therapy Using Autologous Mesenchymal Stem Cell and Mesenchymal Stem Cell Lyophilisate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ukraine Association of Biobank</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ukraine Association of Biobank</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centers of long term safety and efficacy follow up study for patients with&#xD;
      premature ovarian failure (the women aged younger than 40 years, who present with&#xD;
      amenorrhoea, hypergonadotropic hypogonadism, and infertility) who have been treated with ex&#xD;
      vivo gene therapy drug product in Institute of Bio-Stem Cell Rehabilitation UAB - sponsored&#xD;
      clinical studies. After completing the parent clinical study (approximately 6 month),&#xD;
      eligible subject will be followed for additional 2 years for total of 2 years and 6 month&#xD;
      post drug product infusion. No investigation drug product will be administered in the study&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antral follicular count (AFC) serum levels</measure>
    <time_frame>2 years</time_frame>
    <description>Antral follicular count (AFC) &lt;5-7 follicles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>anti-Müllerian hormone (AMH) serum levels</measure>
    <time_frame>2 years</time_frame>
    <description>AMH &lt;0.5-1.1 ng/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regular menstruation and/or pregnancy</measure>
    <time_frame>2 years</time_frame>
    <description>regular menstruation for 5 months and\or pregnancy</description>
  </secondary_outcome>
  <enrollment type="Actual">86</enrollment>
  <condition>Primary Ovarian Insufficiency</condition>
  <condition>Premature Ovarian Failure</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>Product in a Institute of Bio-Stem Cell rehabilitation UAB - sponsored clinical trial who agree to participate in this study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with premature ovarian insufficiency (Diagnostic criteria of ESHRE) who have been&#xD;
        treated with ex vivo gene therapy product in a Institute Bio-Stem Cell Rehabilitation UAB&#xD;
        clinical study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Provision of written informed consent for this study by subjects or as applicable parent&#xD;
        legal guardian. Treated with drug product for therapy of premature ovarian insufficiency in&#xD;
        a Institute Bio-Stem Cell Rehabilitation UAB clinical study.&#xD;
&#xD;
        Diagnosed of premature ovarian insufficiency ESHRE:&#xD;
&#xD;
          -  Women age of 18 to 40 years&#xD;
&#xD;
          -  Have experienced 4 months of oligo/amenorrhea&#xD;
&#xD;
          -  Two serum follicle-stimulating hormone (FSH was &gt;40 mIU/ml levels in the menopausal&#xD;
             range, obtained at least a month apart&#xD;
&#xD;
          -  lower FSH levels ( 25 mIU/ml)&#xD;
&#xD;
          -  anti-Müllerian hormone (AMH) serum levels ( 3.0 ng/ml)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        There are no exclusion criteria for this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Bio-Stem Cell Rehabilitation</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 13, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Premature ovarian failure</keyword>
  <keyword>stem cell therapy</keyword>
  <keyword>mesenchymal stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

